XTX Topco Ltd Purchases Shares of 49,878 Fulcrum Therapeutics, Inc. $FULC

Key Points

• XTX Topco Ltd acquired 49,878 shares of Fulcrum Therapeutics, Inc., representing a new investment valued at approximately $144,000, bringing its ownership to 0.09% of the company.
• Institutional investors and hedge funds now own 89.83% of Fulcrum Therapeutics, with MetLife Investment Management LLC increasing its holdings by 145.8% in the last quarter.
• Fulcrum Therapeutics has received mixed analyst ratings, with a consensus rating of "Hold" and a target price of $7.57, following notable upgrades and downgrades from various firms.

XTX Topco Ltd acquired a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 49,878 shares of the company's stock, valued at approximately $144,000. XTX Topco Ltd owned 0.09% of Fulcrum Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in FULC. BNP Paribas Financial Markets purchased a new stake in Fulcrum Therapeutics in the fourth quarter worth about $38,000. Mariner LLC purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter valued at $78,000. Y Intercept Hong Kong Ltd bought a new position in shares of Fulcrum Therapeutics in the 1st quarter worth $92,000. Cantor Fitzgerald L. P. purchased a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth $94,000. Finally, Zacks Investment Management bought a new stake in Fulcrum Therapeutics during the fourth quarter valued at about $99,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Leerink Partners upgraded shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $4.00 to $12.00 in a report on Friday, May 23rd. Piper Sandler restated an "overweight" rating and issued a $9.00 target price (up from $6.00) on shares of Fulcrum Therapeutics in a research note on Thursday, May 29th. HC Wainwright upgraded Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the company from $4.00 to $12.00 in a report on Tuesday, July 29th. Cantor Fitzgerald upgraded Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price on the stock in a research note on Thursday, May 15th. Finally, Wall Street Zen lowered Fulcrum Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Fulcrum Therapeutics currently has an average rating of "Hold" and a consensus target price of $7.57.

Fulcrum Therapeutics Price Performance

NASDAQ FULC traded down $0.09 on Monday, hitting $6.73. The company had a trading volume of 111,069 shares, compared to its average volume of 585,918. The company has a market capitalization of $364.03 million, a PE ratio of -5.56 and a beta of 2.47. Fulcrum Therapeutics, Inc. has a 12-month low of $2.32 and a 12-month high of $9.90. The company's fifty day moving average price is $7.13 and its 200-day moving average price is $5.19.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. On average, sell-side analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.